Alumis (ALMS) said Wednesday that it has completed its merger with Acelyrin (SLRN).
Each Acelyrin shareholder will receive 0.4814 Alumis share for each Acelyrin share owned. Acelyrin shares have ceased trading on Nasdaq.
"This merger allows us to advance our pipeline through multiple planned key data readouts, with a cash runway that now extends into 2027," Alumis Chairman, CEO and President Martin Babler, said.
Alumis shares were up over 8% in recent trading.
Price: 5.28, Change: +0.40, Percent Change: +8.20